Calyptus Pharmaceuticals and Vistapharm announce ANDA approval for generic version of Brovana
25 August 2022 -

US-based pharmaceutical company Calyptus Pharmaceuticals, Inc. announced on Wednesday that the US Food and Drug Administration granted approval to an Abbreviated New Drug Application (ANDA) for a generic version of Brovana (Arformoterol Tartrate inhalation solution, EQ 0.015mg Base/2ml) to Calyptus' partner - VistaPharm, Inc.

Arformoterol Tartrate inhalation solution, EQ 0.015mg Base/2ml has been co-developed in collaboration with VistaPharm.

The product is intended for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, which includes chronic bronchitis and emphysema. It is for use by nebulisation only.



Related Headlines